VISTA Regulation of T Cell Immunity in Cancer Immunotherapy

VISTA (V-domain Ig suppressor of T cell activation) has emerged as a pivotal immune checkpoint with dual roles in maintaining peripheral tolerance and restraining antitumour immunity. Expressed predominantly on myeloid cells and certain tumour cells, VISTA engages ligands or counter-receptors to dampen T cell activation, proliferation and cytokine secretion. In the tumour microenvironment, its up-regulation contributes to immune evasion by impairing cytotoxic T lymphocyte function and skewing myeloid cell phenotypes towards immunosuppression. Preclinical models have demonstrated that blockade of VISTA rescues T cell effector responses, enhances infiltration of CD8+ lymphocytes and synergises with other checkpoint inhibitors. The spatial and temporal dynamics of VISTA expression, together with its context-dependent regulatory mechanisms—ranging from transcriptional control by STAT3 to pH-sensitive ligand engagement—underscore its promise as a therapeutic target. A deeper understanding of VISTA-mediated pathways is critical for the rational design of combination regimens that overcome resistance to existing immunotherapies and broaden clinical benefit across tumour types.

Research from Nature Portfolio

Recent studies have harnessed structural biology and in vivo models to refine VISTA targeting. A novel pH-selective monoclonal antibody, engineered to bind its unique epitope only under acidic conditions characteristic of the tumour milieu, has shown improved pharmacokinetics and safety profiles. In humanised mouse models bearing syngeneic tumours, this antibody, when combined with a PD-1 inhibitor, remodelled cytokine networks, reinvigorated exhausted T cells and achieved superior tumour control compared to monotherapy. Foundational work has further elucidated how VISTA modulates T cell activation via the IL-23/IL-17 inflammatory axis, revealing that its absence amplifies dendritic cell signalling and Th17-mediated responses. These mechanistic insights clarify VISTA’s homeostatic function in T cell regulation and inform the development of therapies that selectively disrupt its immunosuppressive interactions within tumours.

VISTA Regulation of T Cell Immunity in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in vista regulation of t cell immunity in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

VISTA: A transmembrane immune-checkpoint protein that suppresses T cell activation and shapes myeloid cell function in the tumour microenvironment.

Immune checkpoint: A regulatory pathway in the immune system that modulates T cell responses to maintain self-tolerance and prevent excessive inflammation.

Tumour microenvironment (TME): The complex milieu surrounding a tumour, comprising stromal cells, immune cells, vasculature and signalling molecules that influence tumour growth and treatment response.

Monoclonal antibody: A laboratory-generated protein designed to bind a specific antigen, used therapeutically to block or activate immune pathways.

References

1. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. Journal of Hematology & Oncology (2023).
2. VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nature Communications (2024).
3. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Scientific Reports (2017).
4. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Journal of Hematology & Oncology (2020).
5. VISTA-mediated immune evasion in cancer. Experimental & Molecular Medicine (2024).
6. VISTA expressed in tumour cells regulates T cell function. British Journal of Cancer (2018).
7. A New VISTA on combination therapy for negative checkpoint regulator blockade. Journal for ImmunoTherapy of Cancer (2016).